COMMUNIQUÉS West-GlobeNewswire

BreathEaseX Releases Sublingual Lung Health Spray with CardioEaseX Formula for Easy Breathing Support
13/07/2026
All Ten Ingredients: NAC, Quercetin, Manuka Honey, Vitamin D3, Olive Leaf, L-Theanine, CoQ10, Hawthorn Berry, L-Carnitine, and Magnesium Explained Aurora, CO, July 13, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
13/07/2026
Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, [...]
Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth
13/07/2026
HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, [...]
GutGlucose Releases Latest Ingredients List with Gut Glucose Reset Formula
13/07/2026
Ceylon Cinnamon, Berberine HCl, Banaba Leaf Extract, Saffron, and Fucoxanthin Explained in the GutGlucose Daily Chewable Tablet Formula Largo, FL, July 13, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
13/07/2026
Company announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026
New executive leadership role to accelerate innovation, modernize technology, and advance the company's long-term growth strategy MCLEAN, Va., July 13, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health [...]
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
13/07/2026
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development ZIMA-101 represents the first [...]
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026
England’s biggest pub comes alive for a blockbuster semifinal, delivering the atmosphere, the passion and an unforgettable football watch party as fans rally behind England LONDON, July 13, 2026 (GLOBE NEWSWIRE) -- [...]
Sienna Senior Living Named One of Canada's Best Companies by TIME and Statista for Second Consecutive Year
13/07/2026
MARKHAM, Ontario, July 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") is proud to announce it has been named one of Canada's Best Companies by TIME and Statista for the second [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, [...]
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. [...]
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026
Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark [...]
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative [...]
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial [...]
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
13/07/2026
CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals [...]
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization REHOVOT, Israel and HOBOKEN, N.J., July 13, [...]
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial payer agreements [...]
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE [...]

Pages